Retatrutide

What is Retatrutide?

Retatrutide (LY3437943) is a novel peptide designed to simultaneously activate the GIP, GLP-1, and glucagon receptors. By engaging these pathways, Retatrutide aims to improve metabolic outcomes such as weight reduction and glycemic control. Preliminary clinical studies have demonstrated significant weight loss in participants, highlighting its potential as a therapeutic agent for obesity and related conditions. This compound is intended solely for scientific investigation and is not approved for human or veterinary use.

Structure

• Chemical Formula: C₁₆₈H₂₆₆N₄₀O₅₁
• Synonyms: LY3437943

Retatrutide Research

Retatrutide and Obesity Management

In a phase 2 clinical trial, Retatrutide demonstrated substantial weight loss in adults with obesity. Participants receiving the highest dose experienced a mean weight reduction of 24.2% over 48 weeks. These findings suggest Retatrutide’s potential as a highly effective treatment for obesity. [1]

Retatrutide in Type 2 Diabetes

Retatrutide has shown promise in improving glycemic control among individuals with type 2 diabetes. A study published in The Lancet reported significant reductions in HbA1c levels and body weight in participants treated with Retatrutide, indicating its dual benefit in managing both glucose levels and weight. [2]

Retatrutide’s Impact on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Research indicates that Retatrutide may effectively reduce liver fat content in individuals with MASLD. A study published in Nature Medicine observed significant decreases in liver fat percentage among participants treated with Retatrutide, highlighting its potential role in addressing liver-related metabolic disorders. [3]

Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Referenced Citations

1. Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” The New England Journal of Medicine. 2023;389(1):11–24. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
2. Rosenstock J, Perkovic V, Johannesdottir SA, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo controlled, and active comparator-controlled, phase 2 trial.” The Lancet. 2023;402(10397):1980–1992. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/fulltext
3. Sanyal A, Newsome PN, Garcia-Tsao G, et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.” Nature Medicine. 2023;29:1177–1187. Available at: https://www.nature.com/articles/s41591-024-03018-2